Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae

Molecular Pharmacology

Volumn 68, Issue 5, 2005, Pages 1365-1375

  Hellauer, Karen ^a   Lesage, Guillaume ^a   Sdicu, Anne Marie ^a   Turcotte, Bernard ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; CYTOCHROME P450 OXIDOREDUCTASE; DNA TOPOISOMERASE (ATP HYDROLYSING); OXIDOREDUCTASE; PERMEASE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA REPAIR; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; DRUG UPTAKE; GENE; GENE DELETION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HAPLOIDY; NONHUMAN; ORTHOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; ROBOTICS; SACCHAROMYCES CEREVISIAE; YEAST;

ANTINEOPLASTIC AGENTS; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; GENOMIC INSTABILITY; NADPH-FERRIHEMOPROTEIN REDUCTASE; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION; TRIAZINES;

EID: 27544512786     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.012963     Document Type: Article

References (61)

1. Adams A, Gottschling DE, and Stearns T (1997) Methods in Yeast Genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
2. Aguilar-Uscanga B and Francois JM (2003) A study of the yeast cell wall composition and structure in response to growth conditions and mode of cultivation. Lett Appl Microbiol 37:268-274.
3. Akache B, MacPherson S, Sylvain MA, and Turcotte B (2004) Complex interplay among regulators of drug resistance genes in Saccharomyces cerevisiae. J Biol Chem 279:27855-27860.
4. Alifano P, Fani R, Lio P, Lazcano A, Bazzicalupo M, Carlomagno MS, and Bruni CB (1996) Histidine biosynthetic pathway and genes-structure, regulation and evolution. Microbiol Rev 60:44-69.
5. Aouida M, Page N, Leduc A, Peter M, and Ramotar D (2004) A genome-wide screen in Saccharomyces cerevisiae reveals altered transport as a mechanism of resistance to the anticancer drug bleomycin. Cancer Res 64:1102-1109.
6. Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, Chan DA, Giaccia AJ, and Semenza GL (2005) OS-9 interacts with hypoxia-inducible factor 1α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1α. Mol Cell 17:503-512.
7. Barret JM and Hill BT (1998) DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anticancer Drugs 9:105-123.
8. Battini JL, Rasko JEJ, and Miller AD (1999) A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G proteincoupled signal transduction. Proc Natl Acad Sci USA 96:1385-1390.
9. Becerra M, Lombardia-Ferreira LJ, Hauser NC, Hoheisel JD, Tizon B, and Cerdan ME (2002) The yeast transcriptome in aerobic and hypoxic conditions: effects of hap1, rox1, rox3 and srb10 deletions. Mol Microbiol 45:265.
10. Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Plager C, McIntyre S, and Viallet J (1999) Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anticancer Drugs 10:735-739.
11. Brachmann CB, Davies A, Cost GJ, Caputo E, Li J, Hieter P, and Boeke JD (1998) Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast 14:115-132.
12. Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170.
13. Brown JM (1999) The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain memorial award lecture. Cancer Res 59:5863-5870.
14. Brown JM and Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416.
15. Brown JM and William WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447.
16. Chinje EC, Patterson AV, Saunders MP, Lockyer SD, Harris AL, and Stratford IJ (1999) Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines? Br J Cancer 81:1127-1133.
17. Craighead PS, Pearcey R, and Stuart G (2000) A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 48:791-795.
18. Eide DJ (1998) The molecular biology of metal ion transport in Saccharomyces cerevisiae. Ann Rev Nutr 18:441-469.
19. Evans JW, Yudoh K, Delahoussaye YM, and Brown JM (1998) Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58:2098-2101.
20. Forsberg H, Hammar M, Andreasson C, Moliner A, and Ljungdahl PO (2001) Suppressors of ssy1 and ptr3 null mutations define novel amino acid sensor-independent genes in Saccharomyces cerevisiae. Genetics 158:973-988.
21. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, and Broder GJ (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838.
22. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, and Vaupel P (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26:45-50.
23. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai HY, He YDD, et al. (2000) Functional discovery via a compendium of expression profiles. Cell 102:109-126.
24. Ishida S, Lee J, Thiele DJ, and Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298-14302.
25. Krantz M, Nordlander B, Valadi H, Johansson M, Gustafsson L, and Hohmann S (2004) Anaerobicity prepares Saccharomyces cerevisiae cells for faster adaptation to osmotic shock. Eukaryot Cell 3:1381-1390.
26. Lambeth JD, Cheng G, Arnold RS, and Edens WA (2000) Novel homologs of gp91phox. Trends Biochem Sci 25:459-461.
27. Lesuisse E, Casterassimon M, and Labbe P (1996) Evidence for the Saccharomyces cerevisiae ferrireductase system being a multicomponent electron transport chain. J Biol Chem 271:13578-13583.
28. Li Z and Brendel M (1994) Sensitivity to nitrogen mustard in Saccharomyces cerevisiae is independently determined by regulated choline permease and DNA repair. Mutat Res 315:139-145.
29. Lin XJ, Okuda T, Holzer A, and Howell SB (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62:1154-1159.
30. Litovchick L, Friedmann E, and Shaltiel S (2002) A selective interaction between OS-9 and the carboxyl-terminal tail of meprin β. J Biol Chem 277:34413-34423.
31. Lloyd RV, Duling DR, Rumyantseva GV, Mason RP, and Bridson PK (1991) Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol 40:440-445.
32. Mnaimneh S, Davierwala AP, Haynes J, Moffat J, Peng WT, Zhang W, Yang XQ, Pootoolal J, Chua G, Lopez A, et al. (2004) Exploration of essential gene functions via titratable promoter alleles. Cell 118:31-44.
33. Nitiss JL (2002) A copper connection to the uptake of platinum anticancer drugs. Proc Natl Acad Sci USA 99:13963-13965.
34. Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, and Wang JC (1992) Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 52:4467-4472.
35. Nordsmark M, Overgaard M, and Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41:31-39.
36. Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C, and Vaupel P (1993) Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 26:631-636.
37. Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR, and Boone C (2004) Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 22:62-69.
38. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, and Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72:1144-1150.
39. Patterson AV, Saunders MP, Chinje EC, Patterson LH, and Stratford IJ (1998) Enzymology of tirapazamine metabolism: a review. Anticancer Drug Design 13:541-573.
40. Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, and Strafford IJ (1997) Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76:1338-1347.
41. Peters KB and Brown JM (2002) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62:5248-5253.
42. Peters KB, Wang HY, Brown JM, and Iliakis G (2001) Inhibition of DNA replication by tirapazamine. Cancer Res 61:5425-5431.
43. Prakash S and Prakash L (2000) Nucleotide excision repair in yeast. Mutat Res 451:13-24.
44. Regenberg B, During-Olsen L, Kielland-Brandt MC, and Holmberg S (1999) Substrate specificity and gene expression of the amino-acid permeases in Saccharomyces cerevisiae. Curr Genet 36:317-328.
45. Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I, and von Roemeling R (2001) Phase I trial of concurrent tirapazamine, cisplatin and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19:535-542.
46. Rooseboom M, Commandeur JNM, and Vermeulen NPE (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53-102.
47. Saunders MP, Patterson AV, Chinje EC, Harris AL, and Stratford IJ (2000) NADPH: cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer 82:651-656.
48. Schreve JL and Garrett JM (2004) Yeast Agp2p and Agp3p function as amino acid permeases in poor nutrient conditions. Biochem Biophys Res Commun 313:745-751.
49. Seddon B, Kelland LR, and Workman P (2004) Bioreductive prodrugs for cancer therapy, in Suicide Gene Therapy: Methods and Reviews (Springer CJ ed) pp 515-542, Methods in Molecular Medicine, Vol 90, Humana Press, Totowa, NJ.
50. Siim BG, van Zijl PL, and Brown JM (1996) Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer 73:952-960.
51. Soetens O, De Craene JO, and André B (2001) Ubiquitin is required for sorting to the vacuole of the yeast general amino acid permease, Gap1. J Biol Chem 276:43949-43957.
52. Su YA, Hutter CM, Trent JM, and Meltzer PS (1996) Complete sequence analysis of a gene (Os-9) ubiquitously expressed in human tissues and amplified in sarcomas. Mol Carcinog 15:270-275.
53. Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13:139-168.
54. Tong AHY, Evangelista M, Parsons AB, Xu H, Bader GD, Page N, Robinson M, Raghibizadeh S, Hogue CWV, Bussey H, et al. (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science (Wash DC) 294:2364-2368.
55. Tong AHY, Lesage G, Bader GD, Ding HM, Xu H, Xin XF, Young J, Berriz GF, Brost RL, Chang M, et al. (2004) Global mapping of the yeast genetic interaction network. Science (Wash DC) 303:808-813.
56. Verna J, Lodder A, Lee K, Vagts A, and Ballester R (1997) A family of genes required for maintenance of cell wall integrity and for the stress response in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 94:13804-13809.
57. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, et al. (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 18:1351-1359.
58. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692.
59. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, Bangham R, Benito R, Boeke JD, Bussey H, et al. (1999) Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science (Wash DC) 285:901-906.
60. Wouters BG, Delahoussaye YM, Evans JW, Birrell GW, Dorie MJ, Wang JL, MacDermed D, Chiu RK, and Brown JM (2001) Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res 61:145-152.
61. Wu HI, Brown JA, Dorie MJ, Lazzeroni L, and Brown JM (2004) Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin and mitomycin C. Cancer Res 64:3940-3948.